This week’s pre-holiday news roundup includes a Waltham biotech’s cardiometabolic collaboration with Novo Nordisk, Akari ...

Novo Holdings has completed the previously announced acquisition of Catalent in a $16.5bn all-cash transaction. The European ...

That's why Novo Nordisk's shares are worth sticking with for good, and at about $108 apiece, investors can afford two of them ...

The U.S. Food and Drug Administration said on Thursday there was no longer a shortage of Eli Lilly's blockbuster weight loss ...

Eli Lilly just gave investors several reasons to cheer.

The U.S. Food and Drug Administration said on Thursday that Eli Lilly's weight-loss drug shortage has been resolved, ...

Does Warren Buffett have a secret portfolio? The holdings you see listed in Berkshire Hathaway's regulatory filings aren't ...

As Novo Nordisk and Eli Lilly expand sales of their popular diabetes and weight-loss drugs, cheaper copies of their patented ...

When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion in sales in 2023, it shows no ...

With U.S. headquarters in Plainsboro, Novo Nordisk told NJBIZ, "NAION is a very rare eye disease, and it is not an adverse ...

Recently published studies assert that Ozempic significantly increases the risk of developing a rare eye condition called non ...